WHO Guideline Development Group advises against use of remdesivir for covid-19

▴ WHO Guideline Development Group advises against use of remdesivir for covid-19
Currently no evidence that it improves survival and other important measures

The antiviral drug remdesivir is not suggested for patients admitted to hospital with covid-19, regardless of how severely ill they are, because there is currently no evidence that it improves survival or the need for ventilation, say a WHO Guideline Development Group (GDG) panel of international experts in The BMJ recently.

The recommendation is part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of covid-19 and help doctors make better decisions with their patients.

Living guidelines are useful in fast moving research areas like covid-19 because they allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19 and is increasingly used to treat patients in hospital. But its role in clinical practice has remained uncertain.

Today’s recommendation is based on a new evidence review comparing the effects of several drug treatments for covid-19. It includes data from four international randomised trials involving over 7,000 patients hospitalised for covid-19.

After thoroughly reviewing this evidence, the WHO GDG expert panel, which includes experts from around the world including four patients who have had covid-19, concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement.

The panel acknowledged that the certainty of evidence is low and said the evidence did not prove that remdesivir has no benefit; rather, there is no evidence based on currently available data that it does improve important patient outcomes.

But given the remaining possibility of important harm, as well as the relatively high cost and resource implications associated with remdesivir (it must be given intravenously), they judged this to be an appropriate recommendation.

They also support continued enrolment into trials evaluating remdesivir, especially to provide higher certainty of evidence for specific groups of patients.

In a linked feature article, US journalist Jeremy Hsu asks what now for remdesivir, given that it is unlikely to be the lifesaving drug for the masses that many have hoped for?

The full story of remdesivir will not be known until manufacturer Gilead releases the full clinical study reports, writes Hsu, but much will depend on whether future studies are designed to test remdesivir’s potential effectiveness.

In the meantime, he says alternative treatments, such as the well known, cheap, and widely available corticosteroid dexamethasone, that has been proved to reduce mortality among severely ill covid-19 patients, are now impacting discussions about remdesivir’s cost-effectiveness.

Tags : #AntiviralDrugRemdesivir #WHO #TheBMJ #MAGICEvidenceEcosystemFoundation #LatestPharmaNews20thNov #LatestResearhonCOVIDTreatment #GileadSciences

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

1,031 new cases of COVID-19 confirmed in Himachal PradeshNovember 25, 2020
Cooking with wood may cause lung damageNovember 25, 2020
More than 56 lakh sample tests for COVID-19 conducted in OdishaNovember 25, 2020
COVID-19 recovery rate in Bihar improves to 97.30 pctNovember 25, 2020
Green Mediterranean (‘green Med’) diet may be even better for healthNovember 25, 2020
Chhattisgarh: Intensive Covid screening of all passengers to be done mandatorily at airportsNovember 25, 2020
New guidance issued on policies to protect populations in vulnerable situations in context of COVID-19November 25, 2020
Life Extension® Launches Bloat Relief Formula.November 25, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR TestingNovember 25, 2020
Bristol Myers Squibb Receives European Commission Approval for OpdivoNovember 25, 2020
QualTex Laboratories adds Ortho Diagnostics VITROS® Anti-SARS-CoV-2 IgG assayNovember 25, 2020
China resorts to rigorous measures after multiple locally transmitted coronavirus cases detected in three citiesNovember 25, 2020
National COVID-19 recovery rate reaches 93.72 pctNovember 25, 2020
Nearly 11,60,000 COVID samples tested in country in last 24 hoursNovember 25, 2020
Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysisNovember 25, 2020
Taking the Pill may cut risk of severe asthma bouts in women of reproductive ageNovember 25, 2020
Multilateral cooperation is key to overcoming global challenges such as COVID-19: Dr Harsh VardhanNovember 25, 2020
Polaryx Therapeutics receives both rare pediatric disease and orphan drug designations from US FDANovember 25, 2020
Panaxia and Neuraxpharm expand strategic collaboration to France with medical cannabisNovember 25, 2020
6,224 new cases of COVID-19 detected in DelhiNovember 25, 2020